Yi Pan

PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy

Yi‐Long Wu, Lin Wu, Nan Bi, Timuçin Çil et autres

BACKGROUND: Consolidation durvalumab following no progression on concurrent chemoradiotherapy (cCRT) is standard of care for unresectable stage III non-small-cell lung cancer (NSCLC). However, in clinical practice many patients receive sequential CRT (sCRT). The PACIFIC-5 trial aimed to evaluate the efficacy and safety …

cn, us, tw, pl, tr, kr, de (code pays fourni par la source)

Cellular dynamics in cerebrospinal fluid unveils the key regulators of intracranial response to immune checkpoint inhibitors in NSCLC brain metastases

Yang-Si Li, Wenpu Lai, Kai Yin, Hai‐Yan Tu et autres

Background Brain metastases (BrM) in non-small cell lung cancer (NSCLC) present a significant challenge due to poor prognosis. While immune checkpoint inhibitors (ICIs) have been standard treatments for NSCLC, their efficacy in BrM is variable, emphasizing the urgent need for predictive biomarkers …

cn, hk (code pays fourni par la source)

Axillary lymph node dissection offers no survival benefit in breast cancer patients with sentinel lymph node micrometastases after neoadjuvant therapy

Jianing Zhang, Yudong Zhou, Lizhe Zhu, Jiaqi Zhang et autres

The role of axillary lymph node dissection (ALND) in breast cancer patients with sentinel lymph node (SLN) micrometastases, particularly after neoadjuvant therapy, remains debated. The present study aimed to assess whether adding ALND provides a survival benefit in this population. Data were …

cn (code pays fourni par la source)

Identifying low-risk breast cancer patients for axillary biopsy exemption: a multimodal preoperative predictive model

Jiaqi Zhang, Jianing Zhang, Zhihao Liu, Yudong Zhou et autres

BACKGROUND: As the most prevalent female malignancy worldwide, breast cancer frequently involves axillary lymph node metastasis (ALNM), which critically affects therapeutic algorithms. Current guidelines mandate preoperative ultrasound-guided axillary biopsy for suspicious lymph nodes, potentially exposing some low-risk patients with negative results to …

cn (code pays fourni par la source)

The DCIS–IBC guide board on predicting postoperative upgrading in breast ductal carcinoma in situ: clinical insights from a multicenter study

Chaorui Duan, Juan Du, Lizhe Zhu, Dong Fan et autres

BACKGROUND: Ductal carcinoma in situ (DCIS) carries a significant risk of postoperative upgrading to invasive breast cancer (IBC), yet existing prediction models lack validation in Asian populations. This study aimed to develop and validate a population-specific nomogram to preoperatively predict DCIS-to-IBC upgrading …

cn (code pays fourni par la source)

A phase II exploratory study (NCT06208826) on maintenance immunotherapy in patients with resectable locally advanced head and neck cancer who achieved MPR after neoadjuvant immunotherapy combined with chemotherapy.

Hongling Wang, Xudong Wang, Yanwei Li, Peiguo Wang et autres

e18083 Background: Induction chemotherapy could improve functional preservation but could not provide long-term survival benefits in head and neck squamous cell carcinoma (HNSCC). Immunotherapy has achieved great success in the salvage treatment of recurrence and metastasis HNSCC. Many clinical studies have found …

cn (code pays fourni par la source)

Neoadjuvant PD-1 inhibitor combined with Nab-paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NCT05522985): A randomized, controlled, open label, phase II clinical trial.

Hongling Wang, Xudong Wang, Yanwei Li, Peiguo Wang et autres

6018 Background: More than 60% of head and neck squamous cell carcinoma (HNSCC) patients (pts) were locally advanced at diagnosis. Many previous clinical trials have confirmed that induction chemotherapy can improve the functional retention rate of HNSCC and improve the quality of …

cn (code pays fourni par la source)

Manganese superoxide dismutase- cell-penetrating peptide fusion protein supplementation as a novel strategy for the effective cryopreservation of Portuguese oyster Crassostrea angulata oocytes

C. C. Cheng, Dillirani Nagarajan, Wen-Jie You, Yi Pan et autres

tw, ye (code pays fourni par la source)

Supplementary Table S4 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer

Jia‐Tao Zhang, Si‐Yang Liu, Xuan Gao, Si‐Yang Maggie Liu et autres

Table S4. Clinical characteristics of 13 cases recurred with longitudinal undetected MRD.

Supplementary Table S6 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer

Jia‐Tao Zhang, Si‐Yang Liu, Xuan Gao, Si‐Yang Maggie Liu et autres

Table S6. The circulating tumor DNA mutation results for 4 patients with lead time over 30 months.

Supplementary Table S1 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer

Jia‐Tao Zhang, Si‐Yang Liu, Xuan Gao, Si‐Yang Maggie Liu et autres

Table S1. Performance Metrics of Landmark and Longitudinal MRD Analyses Stratified by Tumor Type.

Supplementary Figure S3 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer

Jia‐Tao Zhang, Si‐Yang Liu, Xuan Gao, Si‐Yang Maggie Liu et autres

Supplementary Figure S3. (A) Kaplan–Meier analysis of disease-free survival (DFS) stratified by landmark MRD status for LUAD patients. (B) Kaplan–Meier analysis of DFS stratified by longitudinal MRD status for LUAD patients. (C) Kaplan-Meier analysis of the survival time since last blood, comparing …